Cantor Fitzgerald upgraded Supernus (SUPN) to Overweight from Neutral with a price target of $42, up from $36.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Supernus Pharmaceuticals Holds Annual Stockholders Meeting
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist